Pharmicell Co., Ltd.
KSC: 005690.KS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Korea Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Hyun-Soo Kim
- Employees
- 136
- Headquarters
- Seoul, South Korea
- IPO year
- 2000
- Market cap
- ₩1.2T
- Website
- https://www.pharmicell.com
Loading 005690…
Loading profile data…Frequently asked questions about 005690
What does Pharmicell Co., Ltd. (005690.KS) do?
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in...
Where does 005690.KS trade?
Pharmicell Co., Ltd. (005690.KS) trades on the Korea Exchange.
What sector is 005690.KS in?
Pharmicell Co., Ltd. (005690.KS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Pharmicell Co., Ltd.?
Hyun-Soo Kim is the chief executive officer of Pharmicell Co., Ltd. (005690.KS).
Where is Pharmicell Co., Ltd. headquartered?
Pharmicell Co., Ltd. is headquartered in South Korea.
Does 005690.KS pay a dividend?
Yes — Pharmicell Co., Ltd. (005690.KS) paid a trailing twelve-month dividend of KRW 50.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 005690.KS go public?
Pharmicell Co., Ltd. (005690.KS) completed its initial public offering in 2000.